Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis

Publisher： John Wiley & Sons Inc

E-ISSN： 1755-148x|31|2|341-344

ISSN： 1755-1471

Source： PIGMENT CELL & MELANOMA RESEARCH, Vol.31, Iss.2, 2018-03, pp. : 341-344

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 28, Iss. 5, 2015-09 ,pp. : 607-610

John Wiley & Sons Inc

Access to resources Recommend Favorite

The broad‐spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF‐mutant melanoma cells in combination with other signaling pathway inhibitors

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 28, Iss. 4, 2015-07 ,pp. : 417-430

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phosphoproteomic analysis of basal and therapy‐induced adaptive signaling networks in BRAF and NRAS mutant melanoma

By  

PROTEOMICS, Vol. 15, Iss. 2-3, 2015-01 ,pp. : 327-339

John Wiley & Sons Inc

Access to resources Recommend Favorite

Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma

By Chan Xian Yang   Singh Alamdeep   Osman Narin   Piva Terrence J.  

International Journal of Molecular Sciences, Vol. 18, Iss. 7, 2017-07 ,pp. : 1527-1527

MDPI

Access to resources Recommend Favorite

BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy

By Dörrie Jan   Babalija Lek   Hoyer Stefanie   Gerer Kerstin F.   Schuler Gerold   Heinzerling Lucie   Schaft Niels  

International Journal of Molecular Sciences, Vol. 19, Iss. 1, 2018-01 ,pp. : 289-289

MDPI

Access to resources Recommend Favorite